Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
JAPANESE PATENT GRANTS FOR IMP321
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of patent
number 5908210 entitled Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response by the Japanese Patent Office.
This patent relates to Prima s IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an
increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima s AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
Prima BioMed is a globally active biotechnology company positioned to become a leader in the development of immunotherapeutic products for the treatment of
cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Prima s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune
response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov
identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). A number of additional LAG-3 products including antibodies for immune response
modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Prima BioMed is listed on the Australian Securities Exchange
and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact:
Mr Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australia Investor/Media:
Mr Matthew Gregorowski,
+61 2 8234 0100; mgregorowski@citadelmagnus.com
Prima BioMed Ltd, Level 12, 95 Pitt Street, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889